Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in USD (TTM)1.41bn
- Net income in USD-327.78m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United Therapeutics Corporation | 2.50bn | 1.05bn | 12.26bn | 1.17k | 13.08 | 2.29 | 11.09 | 4.91 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Viatris Inc | 15.36bn | -56.10m | 12.95bn | 38.00k | -- | 0.6468 | 4.89 | 0.8429 | -0.0499 | -0.0499 | 12.75 | 16.81 | 0.3179 | 2.33 | 5.29 | 404,242.10 | -0.1161 | 0.0887 | -0.1356 | 0.1061 | 43.26 | 40.29 | -0.3652 | 0.2891 | 1.17 | 2.63 | 0.473 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Incyte Corp | 3.77bn | 745.44m | 13.07bn | 2.52k | 17.67 | 2.42 | 15.73 | 3.47 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
BIO-TECHNE Corp | 1.15bn | 202.97m | 13.08bn | 3.05k | 65.98 | 6.49 | 41.70 | 11.33 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Natera Inc | 1.21bn | -365.46m | 13.33bn | 3.28k | -- | 16.70 | -- | 11.03 | -3.13 | -3.13 | 10.31 | 6.50 | 0.8673 | 14.36 | 4.51 | 368,237.70 | -26.23 | -36.17 | -33.37 | -46.60 | 50.28 | 45.88 | -30.24 | -56.15 | 3.98 | -- | 0.3141 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.03bn | 1.45k | 38.31 | 5.88 | 35.78 | 7.08 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Biomarin Pharmaceutical Inc | 2.47bn | 205.46m | 14.52bn | 3.40k | 72.37 | 2.86 | 46.71 | 5.87 | 1.06 | 1.06 | 12.77 | 26.74 | 0.3715 | 0.4993 | 4.00 | 726,740.40 | 3.09 | 0.7773 | 3.54 | 0.8825 | 79.22 | 76.30 | 8.31 | 2.24 | 1.70 | -- | 0.1766 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 19.09bn | 2.10k | -- | -- | -- | 9.53 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
argenx SE - ADR | 1.41bn | -327.78m | 22.01bn | 1.15k | -- | -- | -- | 15.63 | -5.66 | -5.66 | 24.30 | -- | -- | -- | -- | 1,226,635.00 | -- | -17.65 | -- | -19.79 | 89.87 | -- | -23.28 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
ICON PLC | 8.23bn | 683.12m | 26.21bn | 41.10k | 38.46 | 2.78 | 20.58 | 3.18 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Holder | Shares | % Held |
---|---|---|
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 5.09m | 8.56% |
Artisan Partners LPas of 31 Mar 2024 | 3.19m | 5.37% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.08m | 5.18% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 2.20m | 3.71% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 2.12m | 3.56% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.86m | 3.14% |
Avoro Capital Advisor LLCas of 31 Mar 2024 | 1.24m | 2.08% |
Bellevue Asset Management AGas of 31 Mar 2024 | 811.02k | 1.37% |
RTW Investments LPas of 31 Mar 2024 | 667.20k | 1.12% |
ClearBridge Investments LLCas of 31 Mar 2024 | 596.28k | 1.00% |